Viral Vector and Plasmid DNA
Manufacturing Market was valued at $261 million in 2016, and is
projected to reach $1,090 million by 2023, growing at a CAGR of 22.6% from 2017
to 2023. North America was the highest contributor to the viral vectors and
plasmid DNA manufacturing market in 2016; however, Asia-Pacific is expected to
witness the highest growth rate throughout the forecast period.
Gene therapy comprises tools such as viral
vectors and plasmid DNA, which have evolved as a favorable treatment option for
various diseases (especially those that currently have no cure) such as viral
infections, cancer, and inherited disorders. Gene therapy and genetically
modified therapy involve the use of a therapeutic DNA (the gene of interest) in
cells. The process of gene transfer into the cells is achieved by the
application of vectors. Over the past few years, several viral and non-viral
plasmid DNAs have been standardized and optimized for this purpose.
Download PDF Report
Sample with statistical info @ https://www.alliedmarketresearch.com/request-sample/2681
The major factors that drive the global viral
vectors and plasmid DNA manufacturing market include rise in the number of
candidates of gene therapy combined with their swift development through the
numerous phases of clinical progression, ability of vectors to express
therapeutic genes efficiently, and nonpathogenic nature of vectors. However,
possible insertional mutagenesis and high cost of gene therapies impede the
market growth. Technological advancements to alleviate challenges caused by
traditional methods of vector production provide lucrative opportunities for
the manufacturers in this industry.
The key market players operating in this
market are Kaneka Eurogentec S.A., FinVector, Brammer Bio, Cell and Gene
Therapy Catapult, FUJIFILM Diosynth Biotechnologies, Sanofi, Spark
Therapeutics, Cobra Biologics, UniQure and MassBiologics. Other players in the
value chain analysis include, 4D Molecular Therapeutics, Renova Therapeutics,
Shenzhen SiBiono GeneTech Co., Ltd., and Thermo Fisher Scientific, Inc.
The cancer application generated the highest
revenue of $162 million in 2016, and is anticipated to continue this trend in
the future. The requirement for quality drugs and versatile therapies for
treatment are expected to boost the growth of this segment. Inherited disorders
application is projected to grow at the highest CAGR of 25.1% from 2017 to
2023.
North America held the highest market share of
$124 million in 2016, owing to high prevalence rate of cancer and modern
healthcare facilities. The adoption of experimental medicines and growth in
awareness about gene therapy are expected to boost the North American market.
Asia-Pacific is expected to grow at the highest CAGR of 18.8% during the
forecast period, owing to rapid industrialization in the area, increase in
disposable income, and upsurge in government initiatives to modernize
healthcare infrastructure.
Key Findings of
the Viral Vector and Plasmid DNA Manufacturing Market:
- The plasmid DNA segment is anticipated to
grow at the highest CAGR from 2017 to 2023.
- The inherited disorders application segment
is expected to witness the highest growth rate.
- Cancer application segment is anticipated
to occupy the largest share in the viral vector and plasmid DNA
manufacturing market.
- North America dominated the global viral
vector and plasmid DNA manufacturing market, and is projected to grow at a
CAGR of 20.6%.
No comments:
Post a Comment